AbbVie (ABBV) Current Assets (2012 - 2026)
AbbVie (ABBV) posted quarterly Current Assets of $33.5 billion for Q1 2026, up 21.15% year-over-year from $27.7 billion in Q1 2025, and up 15.37% quarter-over-quarter from $29.1 billion in Q4 2025.
AbbVie (ABBV) Current Assets (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Current Assets for 15 consecutive years, with $33.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 21.15% year-over-year to $33.5 billion; the TTM figure through Mar 2026 stood at $33.5 billion (up 21.15% YoY), while the FY2025 annual figure was $29.1 billion, up 13.6% from the prior year.
- Current Assets grew to $33.5 billion in Q1 2026 per ABBV's latest filing, from $29.1 billion in the prior quarter.
- Across five years, Current Assets topped out at $38.9 billion in Q1 2024 and bottomed at $25.6 billion in Q4 2024.
- Historically, Current Assets has averaged $30.0 billion across 5 years, with a median of $29.1 billion in 2025.
- Annual changes were most pronounced in 2024 — Current Assets jumped 46.75% — and 2025, when it decreased 28.8%.
- AbbVie's Current Assets stood at $28.5 billion in 2022, then increased by 15.95% to $33.0 billion in 2023, then decreased by 22.48% to $25.6 billion in 2024, then rose by 13.6% to $29.1 billion in 2025, then gained by 15.37% to $33.5 billion in 2026.
- Business Quant data shows ABBV's Current Assets at $33.5 billion in Q1 2026, $29.1 billion in Q4 2025, and $28.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 648.58 Bn | 627.82 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 466.01 Bn | 459.44 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 375.19 Bn | 368.05 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 300.09 Bn | 292.40 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 256.64 Bn | 251.74 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 235.38 Bn | 221.39 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 180.78 Bn | 177.60 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 159.94 Bn | 148.24 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.22 Bn | 101.06 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.77 Bn | 47.39 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.67 Bn |
| Mar 31, 2026 | 33.53 Bn |
| Dec 31, 2025 | 29.06 Bn |
| Sep 30, 2025 | 28.54 Bn |
| Jun 30, 2025 | 29.26 Bn |
| Mar 31, 2025 | 27.68 Bn |
| Dec 31, 2024 | 25.58 Bn |
| Sep 30, 2024 | 27.79 Bn |
| Jun 30, 2024 | 33.82 Bn |
| Mar 31, 2024 | 38.87 Bn |
| Dec 31, 2023 | 33.00 Bn |
| Sep 30, 2023 | 33.22 Bn |
| Jun 30, 2023 | 28.85 Bn |
| Mar 31, 2023 | 26.49 Bn |
| Dec 31, 2022 | 28.46 Bn |
| Sep 30, 2022 | 30.36 Bn |
| Jun 30, 2022 | 29.10 Bn |
| Mar 31, 2022 | 26.51 Bn |
| Dec 31, 2021 | 27.93 Bn |
| Sep 30, 2021 | 28.96 Bn |